Recent Advancement in mRNA Vaccine Development and Applications

被引:56
作者
Al Fayez, Nojoud [1 ]
Nassar, Majed S. [1 ]
Alshehri, Abdullah A. [1 ]
Alnefaie, Meshal K. [1 ]
Almughem, Fahad A. [1 ]
Alshehri, Bayan Y. [1 ]
Alawad, Abdullah O. [2 ]
Tawfik, Essam A. [1 ]
机构
[1] King Abdulaziz City Sci & Technol KACST, Adv Diag & Therapeut Inst, Hlth Sect, Riyadh 11442, Saudi Arabia
[2] King Abdulaziz City Sci & Technol KACST, Hlth Aging Res Inst, Hlth Sect, Riyadh 11442, Saudi Arabia
关键词
mRNA vaccine; delivery; lipid nanoparticles (LNPs); infectious diseases; cancer; immune response; PHASE-I TRIAL; COVID-19; VACCINES; CIRCULAR RNAS; CAP-ANALOGS; DELIVERY; NANOPARTICLES; THERAPEUTICS; TRANSLATION; MECHANISMS; PROTECTION;
D O I
10.3390/pharmaceutics15071972
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Messenger RNA (mRNA) vaccine development for preventive and therapeutic applications has evolved rapidly over the last decade. The mRVNA vaccine has proven therapeutic efficacy in various applications, including infectious disease, immunotherapy, genetic disorders, regenerative medicine, and cancer. Many mRNA vaccines have made it to clinical trials, and a couple have obtained FDA approval. This emerging therapeutic approach has several advantages over conventional methods: safety; efficacy; adaptability; bulk production; and cost-effectiveness. However, it is worth mentioning that the delivery to the target site and in vivo degradation and thermal stability are boundaries that can alter their efficacy and outcomes. In this review, we shed light on different types of mRNA vaccines, their mode of action, and the process to optimize their development and overcome their limitations. We also have explored various delivery systems focusing on the nanoparticle-mediated delivery of the mRNA vaccine. Generally, the delivery system plays a vital role in enhancing mRNA vaccine stability, biocompatibility, and homing to the desired cells and tissues. In addition to their function as a delivery vehicle, they serve as a compartment that shields and protects the mRNA molecules against physical, chemical, and biological activities that can alter their efficiency. Finally, we focused on the future considerations that should be attained for safer and more efficient mRNA application underlining the advantages and disadvantages of the current mRNA vaccines.
引用
收藏
页数:24
相关论文
共 177 条
[21]   Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis [J].
Choi, Angela ;
Koch, Matthew ;
Wu, Kai ;
Chu, Laurence ;
Ma, LingZhi ;
Hill, Anna ;
Nunna, Naveen ;
Huang, Wenmei ;
Oestreicher, Judy ;
Colpitts, Tonya ;
Bennett, Hamilton ;
Legault, Holly ;
Paila, Yamuna ;
Nestorova, Biliana ;
Ding, Baoyu ;
Montefiori, David ;
Pajon, Rolando ;
Miller, Jacqueline M. ;
Leav, Brett ;
Carfi, Andrea ;
McPhee, Roderick ;
Edwards, Darin K. .
NATURE MEDICINE, 2021, 27 (11) :2025-+
[22]   Efficient mRNA delivery with graphene oxide-polyethylenimine for generation of footprint-free human induced pluripotent stem cells [J].
Choi, Hye Yeon ;
Lee, Tae-Jin ;
Yang, Gwang-Mo ;
Oh, Jaesur ;
Won, Jihye ;
Han, Jihae ;
Jeong, Gun-Jae ;
Kim, Jongpil ;
Kim, Jin-Hoi ;
Kim, Byung-Soo ;
Cho, Ssang-Goo .
JOURNAL OF CONTROLLED RELEASE, 2016, 235 :222-235
[23]   COVID-19 vaccines: The status and perspectives in delivery points of view [J].
Chung, Jee Young ;
Thone, Melissa N. ;
Kwon, Young Jik .
ADVANCED DRUG DELIVERY REVIEWS, 2021, 170 (170) :1-25
[24]   What went wrong with CureVac's mRNA vaccine? [J].
Cohen, Jon .
SCIENCE, 2021, 372 (6549) :1381-1381
[25]   Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 [J].
Collier, Dami A. ;
Ferreira, Isabella A. T. M. ;
Kotagiri, Prasanti ;
Datir, Rawlings P. ;
Lim, Eleanor Y. ;
Touizer, Emma ;
Meng, Bo ;
Abdullahi, Adam ;
Elmer, Anne ;
Kingston, Nathalie ;
Graves, Barbara ;
Le Gresley, Emma ;
Caputo, Daniela ;
Bergamaschi, Laura ;
Smith, Kenneth G. C. ;
Bradley, John R. ;
Ceron-Gutierrez, Lourdes ;
Cortes-Acevedo, Paulina ;
Barcenas-Morales, Gabriela ;
Linterman, Michelle A. ;
McCoy, Laura E. ;
Davis, Chris ;
Thomson, Emma ;
Lyons, Paul A. ;
McKinney, Eoin ;
Doffinger, Rainer ;
Wills, Mark ;
Gupta, Ravindra K. .
NATURE, 2021, 596 (7872) :417-+
[26]   A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics [J].
Crone, Michael A. ;
Priestman, Miles ;
Ciechonska, Marta ;
Jensen, Kirsten ;
Sharp, David J. ;
Anand, Arthi ;
Randell, Paul ;
Storch, Marko ;
Freemont, Paul S. .
NATURE COMMUNICATIONS, 2020, 11 (01)
[27]   Lipid Nanoparticle Systems for Enabling Gene Therapies [J].
Cullis, Pieter R. ;
Hope, Michael J. .
MOLECULAR THERAPY, 2017, 25 (07) :1467-1475
[28]   BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting [J].
Dagan, Noa ;
Barda, Noam ;
Kepten, Eldad ;
Miron, Oren ;
Perchik, Shay ;
Katz, Mark A. ;
Hernan, Miguel A. ;
Lipsitch, Marc ;
Reis, Ben ;
Balicer, Ran D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) :1412-1423
[29]   A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice [J].
de Alwis, Ruklanthi ;
Gan, Esther S. ;
Chen, Shiwei ;
Leong, Yan Shan ;
Tan, Hwee Cheng ;
Zhang, Summer L. ;
Yau, Clement ;
Low, Jenny G. H. ;
Kalimuddin, Shirin ;
Matsuda, Daiki ;
Allen, Elizabeth C. ;
Hartman, Paula ;
Park, Kyoung-Joo Jenny ;
Alayyoubi, Maher ;
Bhaskaran, Hari ;
Dukanovic, Adrian ;
Bao, Yanjie ;
Clemente, Brenda ;
Vega, Jerel ;
Roberts, Scott ;
Gonzalez, Jose A. ;
Sablad, Marciano ;
Yelin, Rodrigo ;
Taylor, Wendy ;
Tachikawa, Kiyoshi ;
Parker, Suezanne ;
Karmali, Priya ;
Davis, Jared ;
Sullivan, Brian M. ;
Sullivan, Sean M. ;
Hughes, Steve G. ;
Chivukula, Pad ;
Ooi, Eng Eong .
MOLECULAR THERAPY, 2021, 29 (06) :1970-1983
[30]   Targeting mRNA processing as an anticancer strategy [J].
Desterro, Joana ;
Bak-Gordon, Pedro ;
Carmo-Fonseca, Maria .
NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (02) :112-129